other material
confidence high
sentiment positive
materiality 0.80
ARS Pharma licenses neffy to ALK for $145M upfront; up to $320M milestones
ARS Pharmaceuticals, Inc.
- Upfront $145M from ALK; regulatory/commercial milestones up to $20M and sales milestones up to $300M.
- Exclusive license for epinephrine nasal spray (neffy) outside US, Japan, China, Australia, New Zealand for all human uses.
- Tiered royalties in mid-to-high teens on net sales; ARS supplies product for first 5 years under supply agreement.
- ALK must use commercially reasonable efforts for regulatory approval and commercialization; ARS may terminate if ALK sells competing non-injectable epinephrine in US.
- Deal covers anaphylaxis and Type I allergic reactions; parties may agree on future indications.